The Turkish generics market saw sales of $3.4bn in 2010, and has a high growth potential, driven by Turkish generics players' successes in international markets, good manufacturing practice which assists local players, intellectual property laws allowing the earlier launch of generics compared to other European markets, and pharmacist substitution.
Features and benefits
- Insight into the key drivers and resistors to generics uptake in Turkey.
- Assesses strategies employed by the leading generics companies operating in Turkey.
- Analyses biosimilar opportunities in Turkey and factors which could drive or restrict future uptake.
Currently there are no biosimilar products marketed in Turkey. Nevertheless, in 2008 Turkey introduced a biosimilar pathway, which together with favourable data exclusivity requirements could allow prospective biosimilar players a swift market entry.
The fact that all drugs marketed in Turkey require a Turkish good manufacturing practice (GMP) certificate benefits domestic generics players by delaying entry for international generics companies.
A number of Turkish generics companies have entered into agreements with foreign biosimilars players. This circumvents the limited R&D capacity of Turkish manufacturers which restricts the opportunity for a domestically developed biosimilar entering the market anytime soon.
Your key questions answered
- What are the drivers and resistors to generic uptake in Turkey?
- What deal types are companies entering into when looking to enter or bolster their position in the Turkish generics and biosimilars market?
- Which branded biologics and small molecules are facing patent expiry in Turkey?